SCHEMBL15968832

SCHEMBL15968832

COc1cc(-c2nc3cnc(OC[C@H](C)NC(C)=O)cc3o2)ccc1OC[C@@H]1CC1(F)F

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACACB O00763 20/20 0.46
ACACA Q13085 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15968939 1.00 ACACB (0.46) ACACBACACA
SCHEMBL15968587 0.93 ACACB (0.45) ACACBACACA
SCHEMBL15968563 0.92 ACACB (0.47) ACACBACACA
SCHEMBL15968556 0.92 ACACB (0.47) ACACBACACA
SCHEMBL15968650 0.89 ACACB (0.47) ACACBACACA
SCHEMBL15968380 0.88 ACACB (0.51) ACACBACACA
SCHEMBL15968461 0.88 ACACB (0.49) ACACBACACA
SCHEMBL14908367 0.88 ACACB (0.45) ACACB
SCHEMBL15968655 0.85 ACACB (0.48) ACACB
SCHEMBL14908375 0.84 ACACB (0.48) ACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133129-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-15 US disclosed
EP-2772485-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-09-03 EP disclosed
US-20140243310-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243310-A1 BICYCLIC COMPOUND BICRA, NR3C2, CYP11B2 ACACB 1112/4885ACACA 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.